Navigating Uncharted Waters: Steering the Course and Confronting Challenges of Brain Metastases in EGFR-Mutant Non-Small Cell Lung Cancer
Cancers · 17.08.2026 · 18 (16) · 2647
DOI: 10.3390/cancers18162647 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 17.08.2026. Verfasst von Daniela Garcez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Unidade de Tumores Cerebrais, CUF Oncologia, Hospital CUF Descobertas, 1998-018 Lisbon, Portugal. Die Arbeit nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: J&J Innovative Medicine, Johnson & Johnson Innovative Medicine, Portugal.
Abstract (Originalsprache)
Brain metastases represent a major clinical challenge in the management of non-small-cell lung cancer, particularly in patients with epidermal growth factor receptor mutations, constituting a leading cause of morbidity and mortality. In recent years, significant advancements have been made in both local therapies and systemic treatments. Nevertheless, managing central nervous system disease remains complex, encompassing challenges such as optimal therapy sequencing, resistance mechanisms, oligoprogression, the role of the blood–brain barrier, diagnostic strategies, and the influence of the brain tumor microenvironment. Despite advances, brain metastases in non-small-cell lung cancer remain an unmet need. Local treatments like radiotherapy are effective but carry risks of long-term neurological side effects, while the number and burden of brain metastases remain key prognostic factors. Surgical resection may be considered even in patients with multiple brain metastases to improve clinical status, enable further therapy, and enhance survival and quality of life. With the extension of survival afforded by systemic therapies, optimizing the balance between treatment efficacy and quality of life has become critical. Integrating patient perspectives is essential in navigating these complex clinical decisions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unidade de Tumores Cerebrais, CUF Oncologia, Hospital CUF Descobertas, 1998-018 Lisbon, Portugal.
- Unidade de Tumores Cerebrais, CUF Oncologia, Hospital CUF Tejo, 1350-352 Lisbon, Portugal.
- Department of Medical Oncology, Instituto Português de Oncologia do Porto, 4200-162 Porto, Portugal.
- Unidade de Cancro do Pulmão, CUF Oncologia, Hospital CUF Tejo, 1350-352 Lisbon, Portugal.
- Lung Unit Oncology, Fundação Champalimaud, 1400-038 Lisbon, Portugal.
- Department of Radiotherapy, ULS Braga, 4710-243 Braga, Portugal.
ORCID-Profile: Daniela Garcez, Ana Rodrigues, Marcos Pantarotto, António Araújo, Juan Rachadell, João Ramalho-Carvalho, Ana Figueiredo, Telma Sequeira, Maria Gabriela O Fernandes
Förderung
- J&J Innovative Medicine
- Johnson & Johnson Innovative Medicine, Portugal
Zitieren
APA
Garcez, D., Rodrigues, A., Travancinha, C., Pantarotto, M., Costa, P., Araújo, A., Rachadell, J., Ramalho-Carvalho, J., Figueiredo, A., Sequeira, T., & Fernandes, M. G. O. (2026). Navigating Uncharted Waters: Steering the Course and Confronting Challenges of Brain Metastases in EGFR-Mutant Non-Small Cell Lung Cancer. Cancers, 18(16), 2647. https://doi.org/10.3390/cancers18162647
Vancouver
Garcez D, Rodrigues A, Travancinha C, Pantarotto M, Costa P, Araújo A, et al. Navigating Uncharted Waters: Steering the Course and Confronting Challenges of Brain Metastases in EGFR-Mutant Non-Small Cell Lung Cancer. Cancers. 2026;18(16):2647. doi:10.3390/cancers18162647
BibTeX
@article{Garcez2026,
author = {Garcez, Daniela and Rodrigues, Ana and Travancinha, Catarina and Pantarotto, Marcos and Costa, Paulo and Araújo, António and Rachadell, Juan and Ramalho-Carvalho, João and Figueiredo, Ana and Sequeira, Telma and Fernandes, Maria Gabriela O},
title = {Navigating Uncharted Waters: Steering the Course and Confronting Challenges of Brain Metastases in EGFR-Mutant Non-Small Cell Lung Cancer},
journal = {Cancers},
year = {2026},
volume = {18},
number = {16},
pages = {2647},
doi = {10.3390/cancers18162647}
}
EUVIMED